HENGRUI PHARMA announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has recently received a drug clinical trial approval notice from the National Medical Products Administration for HRS9531 injection, with clinical trials to commence in the near future. HRS9531 injection is a novel dual agonist targeting both the gastric inhibitory polypeptide receptor and the glucagon-like peptide-1 receptor, with HRS9531 as its primary active ingredient. It possesses global independent intellectual property rights. The market application for its use in long-term weight management in adults was accepted by the National Medical Products Administration in September 2025. For adolescent patients with overweight and obesity, HRS9531 can activate GIPR and GLP-1R in the body to regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity, thereby improving blood glucose levels and reducing body weight. For this indication, no similar drug has been approved for marketing globally. Additionally, multiple clinical trials for conditions such as type 2 diabetes, obesity with heart failure, obstructive sleep apnea, and obesity with polycystic ovary syndrome are actively advancing. As of now, the cumulative research and development investment for the HRS9531-related project is approximately 632 million yuan.
Comments